Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Passive income is the paycheck that arrives whether you show up or not. Wages depend on a functioning employer, a healthy economy, and the continued willingness of both to keep the seat warm. Dividend income depends on a company writing a check every 90 days, and for a handful of blue chips, that check has ... $500 a Month in These Stocks Will Generate $6,700 in Passive Annual Income
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
These stocks offer high yields, are big names in their respective sectors, and have strong fundamentals.
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.
Pfizer stock is trading in a range where recent returns have been weak over three years, yet the broader valuation checks still lean cheap and suggest the current share price may not fully reflect the company’s fundamentals. Over the past 3 years, Pfizer has delivered a total return that is down about 21%, which shows how much sentiment has cooled since its pandemic peak. The push into oncology and obesity treatments, including recent IBRANCE progress and weight loss drug development, can...
Pfizer (PFE) closed at $24.08 in the latest trading session, marking a -1.19% move from the prior day.
Nike's (NKE) fiscal fourth-quarter revenue slipped year-over-year, while the sportswear company's ea
Nike stock (NKE) is moving lower in Tuesday's extended-hours trading after reporting mixed results for the sportswear brand's fiscal fourth quarter: while earnings topped estimates, revenue declined 1.1% year-over-year. Morningstar senior equity analyst David Swartz discusses what he was expecting from the earnings release and how Nike's performance is lining up with CEO Elliott Hill's turnaround strategy.
Volatility can lower the cost of entry into businesses that throw off real cash, even as investors recognize that a low share price alone is no guarantee of a bargain. Heading into the back half of 2026, three blue-chip names trading well below the $45 mark stand out for the same reason: predictable cash flows, ... 3 Dirt-Cheap Stocks Under $45 Built to Outperform in a Volatile Market
A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...
I keep buying Pfizer (NYSE:PFE) every time my brokerage cash builds up, and I am not slowing down. The market is treating this company like a value trap because COVID revenue is rolling off. I am treating it like a cash machine that just bought itself three extra years of patent life on one of ... Wall Street Walked Away From This Powerhouse Stock, But I Am Buying It on Repeat
CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reimbursement changes test long-term earnings durability.
CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.
CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.
Few large-cap dividends generate as much skepticism as Pfizer (NYSE:PFE). The stock trades at $24.37, and the COVID franchise erosion has been brutal, with Comirnaty down 59% and Paxlovid down 63% in Q1 2026. Yet the dividend keeps coming. I want to know if that 7.27% yield is a gift or a warning. The Dividend ... This 7% Yielding Healthcare Powerhouse Belongs in Retirees’ Portfolios
It could prove to be a case of better later than never for the healthcare giant.
June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according to letters seen by Reuters.
AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with cumulative gains over this period amounting to 17%. The company's market cap has surged by about $65 Bil over the last 5 days and currently stands at $448 Bil.
Is PFE a good stock to buy? We came across a bullish thesis on Pfizer Inc. on r/ValueInvesting by Dismal-Cancel4958. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading at $25.08 as of June 22nd. PFE’s trailing and forward P/E were 19.15 and 8.50 respectively according to Yahoo Finance. Pfizer […]
At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what matters most for a retiree. I dug into each dividend to see which ones a 66-year-old can actually rely on. Bristol Myers Squibb: ... 66 With $1.3 Million. Here Are 3 Hidden Gems to Target
Pfizer Inc. (NYSE:PFE) is among the Best Healthcare Stocks. On June 23, Reuters reported that Pfizer Inc. (NYSE:PFE) ‘s Chief International Commercial Officer, Alexandre de Germay, said China has moved ahead of Europe in pharmaceutical innovation and drug development. De Germay commented that China now has “40% of all clinical studies in oncology” globally. He pointed […]
Things are going from bad to worse for the pharmaceutical giant.
Pfizer (NYSE:PFE) has been dismissed as a defendant in a major federal lawsuit alleging generic drug price fixing. The court found there was not enough evidence to support claims of Pfizer's involvement in alleged collusion. The dismissal removes a legal overhang tied to long running litigation involving multiple generic drugmakers. Pfizer is a large global pharmaceutical company with a portfolio spanning prescription medicines, vaccines, and other healthcare products. For investors...
Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.
The sizable yield comes with a concerning footnote. Just look at the rest of the story.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
